Botulinum toxin A is a neurotoxin produced by the bacterium Clostridium botulinum, which was isolated in 1897 and accidentally discovered to be effective in wrinkle reduction in 1986 by Canadian doctors, Mr. and Mrs. Carruther, when used to treat eye muscle spasms. They subsequently treated forehead lines, frown lines, and crow’s feet one after another, first reported in ’92. Botulinum toxin is divided into eight different antigenic types. Botulinum toxin type A selectively acts on peripheral cholinergic nerves at the neuromuscular junction (synapse), inhibiting the release of acetylcholine from the anterior membrane and blocking the transmission of neurotransmitters, thus causing flaccid paralysis of muscles. The clinical effect usually occurs 48-72 hours after injection when muscle strength decreases significantly. Almost simultaneously the inactivated neuromuscular junction starts to form new neuromuscular junction through normal renewal, repair and germination. When 3-6 months have elapsed, normal function is restored again. Botulinum toxin has been used in the cosmetic field for about 20 years (and in our country for more than 10 years). As a reversible treatment, the method is simple, low cost and reusable. A retrospective study conducted abroad in October 2004 on patients treated for a maximum of nearly 9 years confirmed that the long-term efficacy of repeated application of Botulinum toxin A for cosmetic treatment is safe and acceptable.